Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 464,400 shares, a drop of 22.1% from the February 13th total of 596,500 shares. Based on an average daily trading volume, of 361,600 shares, the short-interest ratio is currently 1.3 days. Approximately 2.2% of the shares of the company are sold short.

Carisma Therapeutics Price Performance

Carisma Therapeutics stock traded up $0.02 during midday trading on Wednesday, hitting $0.42. The company’s stock had a trading volume of 394,182 shares, compared to its average volume of 371,954. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.66. The company has a market capitalization of $17.37 million, a PE ratio of -0.27 and a beta of 1.55. The stock’s 50-day moving average price is $0.45 and its 200-day moving average price is $0.70.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CARM shares. D. Boral Capital reissued a “buy” rating and set a $12.00 price target on shares of Carisma Therapeutics in a report on Monday, January 13th. Evercore ISI reissued an “in-line” rating and set a $0.70 price target (down previously from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $10.00 to $1.00 in a report on Thursday, December 12th. Finally, BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Five analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Carisma Therapeutics has a consensus rating of “Hold” and an average target price of $4.94.

Institutional Trading of Carisma Therapeutics

Hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its stake in Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares in the last quarter. Wexford Capital LP lifted its stake in Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after buying an additional 15,000 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after buying an additional 24,600 shares in the last quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.